BCG vaccine to lower Alzheimer's blood markers
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests whether the BCG vaccine (a tuberculosis vaccine) can lower a blood marker linked to Alzheimer's disease. It is for people aged 70–80 who have slightly elevated p-tau181 levels but still have normal thinking and daily living skills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 70 and 80 years old.
- You feel your memory and thinking skills are normal, and you can do daily tasks like shopping and managing money without help.
- You scored 26 or higher on a standard memory test (MoCA).
- A blood test shows that your p-tau181 level is higher than normal – this is a sign of Alzheimer's-related changes in the brain.
- You do not have Parkinson's, a history of stroke, certain types of dementia, active cancer, severe heart or lung disease, or take immune-suppressing medications. You also do not live with someone who has a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a vaccine that targets tau protein, which is linked to Alzheimer's disease. It is for older adults who have no memory problems yet but have biological signs of early Alzheimer's, to see if the vaccine can prevent or slow down the disease.
This Phase 1 study tests whether stimulating the immune system (through a receptor called TLR9) is safe and may affect brain changes in people with early Alzheimer’s. It mainly enrolls older adults with memory impairment confirmed by specific amyloid imaging.
This trial tests an experimental vaccine (DUVAX) that targets two proteins linked to Alzheimer's disease: amyloid-beta and tau. It is an early-stage study to check safety and see how the body responds, aiming to prevent or delay the disease.
This trial tests a new investigational drug, BMS-986446, given as a single dose to healthy volunteers and multiple doses to people with early Alzheimer's disease. It aims to understand how the drug moves in the body, its safety, and whether it triggers an immune response, which could help guide future treatment for Alzheimer's.
This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
Hear when a new Alzheimer Disease, Late Onset trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.